Toru Mima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toru Mima has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chieko Aoki
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-Oka, Suita City, Osaka 565-0871, Japan
1 shared publication - Hidehiko Sugino
Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-Oka, Suita, Osaka 565-0871, Japan
1 shared publication - Hooi-Ming Lee
Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-Oka, Suita, Osaka 565-0871, Japan
1 shared publication - Kenichi Matsubara
LAC Co., Ltd., Tsukuba 305-0821, Japan
1 shared publication - Naoko Yoshio-Hoshino
Laboratory of Immune Regulation, Graduate School of Frontier Biosciences, Osaka University, 1-3 Yamada-Oka, Suita City, Osaka 565-0871, Japan
1 shared publication Norihiro Nishimoto
1 shared publication
Latest Publications
- Open Access
- 3 January 2009
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 11 (1) , R1
Interactions among type I and type II interferon, tumor necrosis factor, and β-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus
Introduction: Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease characterized by various clinical manifestations. Several cytokines interact and play pathological roles in SLE, although the etiopathology is still obscure. In the present study we investigated the network of immune response-related molecules expressed in the peripheral blood of SLE patients, and the effects of cytokine interactions on the regulation of these molecules. Methods: Gene expression profiles of peripheral blood from SLE patients and from healthy women were analyzed using DNA microarray analysis. Differentially expressed genes classified into the immune response category were selected and analyzed using bioinformatics tools. Since interactions among TNF, IFNγ, β-estradiol (E2), and IFNα may regulate the expression of interferon-inducible (IFI) genes, stimulating and co-stimulating experiments were carried out on peripheral blood mononuclear cells followed by analysis using quantitative RT-PCR. Results: Thirty-eight downregulated genes and 68 upregulated genes were identified in the functional category of immune response. Overexpressed IFI genes were confirmed in SLE patient peripheral bloods. Using network-based analysis on these genes, several networks including cytokines – such as TNF and IFNγ – and E2 were constructed. TNF-regulated genes were dominant in these networks, but in vitro TNF stimulation on peripheral blood mononuclear cells showed no differences in the above gene expressions between SLE and healthy individuals. Co-stimulating with IFNα and one of TNF, IFNγ, or E2 revealed that TNF has repressive effects while IFNγ essentially has synergistic effects on IFI gene expressions in vitro. E2 showed variable effects on IFI gene expressions among three individuals. Conclusions: TNF may repress the abnormal regulation by IFNα in SLE while IFNγ may have a synergistic effect. Interactions between IFNα and one of TNF, IFNγ, or E2 appear to be involved in the pathogenesis of SLE.
- 3 January 2009
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 11 (1) , R1
Open AccessInteractions among type I and type II interferon, tumor necrosis factor, and β-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus
Introduction: Systemic lupus erythematosus (SLE) is a prototypical autoimmune disease characterized by various clinical manifestations. Several cytokines interact and play pathological roles in SLE, although the etiopathology is still obscure. In the present study we investigated the network of immune response-related molecules expressed in the peripheral blood of SLE patients, and the effects of cytokine interactions on the regulation of these molecules. Methods: Gene expression profiles of peripheral blood from SLE patients and from healthy women were analyzed using DNA microarray analysis. Differentially expressed genes classified into the immune response category were selected and analyzed using bioinformatics tools. Since interactions among TNF, IFNγ, β-estradiol (E2), and IFNα may regulate the expression of interferon-inducible (IFI) genes, stimulating and co-stimulating experiments were carried out on peripheral blood mononuclear cells followed by analysis using quantitative RT-PCR. Results: Thirty-eight downregulated genes and 68 upregulated genes were identified in the functional category of immune response. Overexpressed IFI genes were confirmed in SLE patient peripheral bloods. Using network-based analysis on these genes, several networks including cytokines – such as TNF and IFNγ – and E2 were constructed. TNF-regulated genes were dominant in these networks, but in vitro TNF stimulation on peripheral blood mononuclear cells showed no differences in the above gene expressions between SLE and healthy individuals. Co-stimulating with IFNα and one of TNF, IFNγ, or E2 revealed that TNF has repressive effects while IFNγ essentially has synergistic effects on IFI gene expressions in vitro. E2 showed variable effects on IFI gene expressions among three individuals. Conclusions: TNF may repress the abnormal regulation by IFNα in SLE while IFNγ may have a synergistic effect. Interactions between IFNα and one of TNF, IFNγ, or E2 appear to be involved in the pathogenesis of SLE.
- 1 March 2008
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 4 (2) , 165-172
Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab is a humanized anti-human IL-6 receptor antibody that specifically inhibits the biological activity of IL-6 by competitively inhibiting the binding of IL-6 to the IL-6 receptor. Clinical trials have shown that tocilizumab 8 mg/kg administered by monthly infusion not only improves clinical signs and symptoms of refractory rheumatoid arthritis but also suppresses radiographic progression. In regard to safety, the most common adverse event was nonsevere infection, such as nasopharyngitis, although the incident rate of adverse events was slightly higher than that of disease-modifying antirheumatic drug treatment. Studies have shown that there is no specific infection or prolongation of infection related to tocilizumab treatment. Tocilizumab is a promising therapeutic agent with statisfactory efficacy and safety for rheumatoid arthritis.
- 1 March 2008
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 4 (2) , 165-172
Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab is a humanized anti-human IL-6 receptor antibody that specifically inhibits the biological activity of IL-6 by competitively inhibiting the binding of IL-6 to the IL-6 receptor. Clinical trials have shown that tocilizumab 8 mg/kg administered by monthly infusion not only improves clinical signs and symptoms of refractory rheumatoid arthritis but also suppresses radiographic progression. In regard to safety, the most common adverse event was nonsevere infection, such as nasopharyngitis, although the incident rate of adverse events was slightly higher than that of disease-modifying antirheumatic drug treatment. Studies have shown that there is no specific infection or prolongation of infection related to tocilizumab treatment. Tocilizumab is a promising therapeutic agent with statisfactory efficacy and safety for rheumatoid arthritis.